Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases

Tomomi Matsuyama; Masataka Kuwana; Masanori Matsumoto; Ayami Isonishi; Shigeko Inokuma; Yoshihiro Fujimura

doi:10.1160/TH08-12-0825

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2009; 102(02): 371-378
DOI: 10.1160/TH08-12-0825

Cardiovascular Biology and Cell Signalling

Schattauer GmbH

Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases

Tomomi Matsuyama

¹Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Nara, Japan

,

Masataka Kuwana

²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

,

Masanori Matsumoto

¹Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Nara, Japan

,

Ayami Isonishi

¹Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Nara, Japan

,

Shigeko Inokuma

³Rheumatology Center, Japanese Red Cross Medical Center, Tokyo, Japan

,

Yoshihiro Fujimura

¹Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Nara, Japan

› Institutsangaben

Abstract

Summary

To clarify the pathogenic processes of thrombotic microangiopathies (TMAs) in patients with connective tissue disease (CTD), we analysed clinical characteristics and plasma ADAMTS13 levels in 127 patients with CTD-TMAs, including patients with systemic lupus erythematosus (SLE), systemic sclerosis, polymyositis/dermatomyositis, and rheumatoid arthritis (RA), and 64 patients with acquired idiopathic thrombotic thrombocytopenic purpura (ai-TTP). Plasma levels of ADAMTS13 activity, antigen, and inhibitors were determined by enzyme immunoassays. IgG type anti-ADAMTS13 antibodies were also detected by immunoblots using purified ADAMTS13. ADAMTS13 activity was significantly decreased in CTD-TMAs, regardless of the underlying disease, but the frequency of severe deficiency (defined as <0.5% of normal) was lower in CTD-TMA patients than in ai-TTP patients (16.5% vs.70.3%,p<0.01). Severe deficiency of ADAMTS13 activity was predominantly detected in patients with RA and SLE-TMAs, and was closely associated with the presence of anti-ADAMTS13 IgG antibodies. CTD-TMA patients with severe deficiency of ADAMTS13 activity appeared to have lower platelet counts and better therapeutic outcomes. At least two phenotypic TMAs occur in patients with CTDs: a minor population with deficient ADAMTS13 activity caused by neutralising autoantibodies, and a major population with normal or moderately reduced activity. Classifying CTD-TMAs by ADAMTS13 activity may be useful in predicting the clinical course and therapeutic outcomes, as patients with moderately reduced activity are likely to have more prominent renal impairment and poor prognoses.

Keywords

Connective tissue disease - TMA - ADAMTS13 - autoantibody

Volltext

Referenzen

References
1 Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
2 Fujikawa K. et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-1666.
3 Levy GG. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
4 Zheng X. et al. Structure of von Willebrand factorcleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-41063.
5 Soejima K. et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J Biochem (Tokyo) 2001; 130: 475-480.
6 Gerritsen HE. et al. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001; 98: 1654-1661.
7 Plaimauer B. et al. Cloning, expression, and functional characterization of the von Willebrand factorcleaving protease (ADAMTS13). Blood 2002; 100: 3626-3632.
8 Furlan M. et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
9 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
10 Yagi H. et al. Plasma of patients with Upshaw-Schulman syndrome, a congenital deficiency of von Willebrand factor-cleaving protease activity, enhances the aggregation of normal platelets under high shear stress. Br J Haematol 2001; 115: 991-997.
11 Dong JF. et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-4039.
12 Gitlow S, Goldmark C. Generalized capillary and arteriolar thrombosis. Report of two cases with a discussion of the literature. Ann Intern Med 1939; 13: 1046-1067.
13 Levine S, Shearn MA. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus. Arch Intern Med 1964; 113: 826-836.
14 Porta C. et al. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Italian Cooperative Group for TTP. J Rheumatol 1993; 20: 1625-1626.
15 Musio F. et al. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 1998; 28: 1-19.
16 Brunner HI. et al. Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood. Arthritis Rheum 1999; 42: 2346-2355.
17 Güngör T. et al. Acquired deficiency of von Willebrand factor-cleaving protease in a patient suffering from acute systemic lupus erythematosus. Rheumatology (Oxford) 2001; 40: 940-942.
18 Matsumoto M. et al. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol 2004; 41: 68-74.
19 Rick ME. et al. Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura. Am J Hematol 2004; 75: 96-100.
20 Starck M. et al. Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression--report of two cases. Eur J Haematol 2005; 75: 436-440.
21 Enami T. et al. Successful treatment of refractory thrombotic thrombocytopenic purpura with cyclosporine and corticosteroids in a patient with systemic lupus erythematosus and antibodies to ADAMTS13. Intern Med 2007; 46: 1033-1037.
22 Fujimura Y. et al. Thrombotic Microangiopathy. Rec Adv Thromb Hemost 2008; 625-639.
23 Matsumoto M. et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 2004; 103: 1305-1310.
24 Fujimura Y. et al. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol 2009; 144: 742-754.
25 Tan EM. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
26 Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-590.
27 Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-407.
28 Arnett FC. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
29 Ho V. et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: Thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571-575.
30 George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 04: 1927-1935.
31 Ruutu T. et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an international working group. Hematologica 2007; 92: 95-100.
32 Kato S. et al. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 2006; 46: 1444-1452.
33 Tripodi A. et al. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 2008; 06: 1534-1541.
34 Kasper CK. et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
35 Yagi H. et al. Plasma levels of ADAMTS13 antigen determined with an enzyme immunoassay using a neutralizing monoclonal antibody parallel ADAMTS13 activity levels. Int J Hematol 2007; 85: 403-407.
36 Hiura H. et al. Immuno-purification of plasma ADAMTS13 and its physicochemical characterization. J Thromb Haemost. 2007 05. Suppl 2 P-M-295.
37 Uemura M. et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008; 99: 1019-1029.
38 Shimizu M. et al. The significance of ADAMTS13 in a patient with thrombotic thrombocytopenic purpura complicated autoimmune hepatitis. Thromb Haemost 2009; 101: 599-600.
39 Vesely SK. et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-68.
40 Mori Y. et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 2002; 42: 572-580.
41 Zheng XL. et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-4049.
42 Shida Y. et al. Functional imaging of shear-dependent activity of ADAMTS13 in regulating mural thrombus growth under whole blood flow conditions. Blood 2008; 111: 1295-1298.
43 Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001; 14: 437-454.
44 Morioka C. et al. Plasma ADAMTS13 activity parallels the APACHE II score, reflecting an early prognostic indicator for patients with severe acute pancreatitis. Scand J Gastroenterol 2008; 43: 1387-1396.
45 Sato T. et al. Analyses of ADAMTS13 activity and its inhibitor in patients with thrombotic thrombocytopenic purpura secondary to connective tissue diseases: Observations in a single hospital. Clin Exp Rheumatol 2006; 24: 454-455.
46 Török TJ. et al. Increasing mortality from thrombotic thrombocytopenic purpura in the United States-analysis of national mortality data, 1968-1991. Am J Hematol 1995; 50: 84-90.
47 Terrell DR. et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005; 03: 1432-1436.
48 Moake JL. von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Seminar in Hematol 2004; 41: 4-14.
49 Mannucci PM. et al. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 2003; 88: 914-918.
50 Rieger M. et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106: 1262-1267.